Medical condition
Alzheimer
Alzheimer is a medical condition tracked by NovaPharmaNews across 12 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- memantine hydrochloride (MEMANTINE MERZ) Nervous system (N06)
- rivastigmine (EXELON) Nervous system (N06)
- florbetapir (18f) (AMYVID) Various (V09)
- flortaucipir (18f) (TAUVID) Various (V09)
- flutemetamol (18f) (VIZAMYL) Various (V09)
- ioflupane (123i) (CELSUNAX) Various (V09)
- ioflupane (123l) (STRIASCAN) Various (V09)
- memantine (APO-MEMANTINE) Nervous system (N06)
- blarcamesine (BLARCAMESINE ANAVEX) Nervous system (N06)
- florbetaben (18f) (NEURACEQ) Various (V09)
- donanemab (KISUNLA) Nervous system (N06)
- lecanemab (LEQEMBI) Nervous system (N06)
Latest Alzheimer news
Cobenfy meets endpoint in Bristol Myers Squibb’s Alzheimer’s psychosis trial
Bristol Myers Squibb’s Cobenfy has reached a key milestone in Alzheimer’s psychosis, expanding the story beyond its approved schizophrenia use. Analysts should watch ADEPT-2 execution, enrollment changes, and whether the signal supports a broader development path.
Roche reports positive Phase 3 results for trontinemab in Alzheimer's disease
Roche reported positive Phase 3 results for trontinemab in early symptomatic Alzheimer's disease. ClinicalTrials.gov shows two recruiting Phase 3 studies and one earlier Phase 1/2 Brainshuttle AD study.
Eli Lilly's donanemab wins FDA approval for early Alzheimer's disease
The FDA has approved Eli Lilly’s Kisunla (donanemab-azbt) for Alzheimer’s disease, with use to begin in patients with mild cognitive impairment or mild dementia. The decision is a major catalyst for BD teams, investors, and analysts tracking the early Alzheimer’s treatment space.
Biogen's Alzheimer's Data and Leadership Shake-up: Implications for Pharma BD
Biogen faces scrutiny following recent Alzheimer's data releases and executive departures. This analysis explores the implications for pharmaceutical business development and investment strategies.
Bristol Myers' Innovative Approach to Alzheimer's Beyond Amyloid
Bristol Myers is exploring innovative approaches to Alzheimer's treatment that extend beyond amyloid. This article delves into the implications for the pharmaceutical industry.
Axsome FDA Approval for Alzheimer's Agitation Drug
Axsome Therapeutics has received FDA approval for a new treatment for agitation associated with Alzheimer's disease. This landmark decision addresses a critical unmet need and marks a significant step forward for the company and Alzheimer's patient care.
Axsome Therapeutics Receives FDA Approval for AUVELITY to Treat Alzheimer's Agitation - First-in-Class Breakthrough
Axsome Therapeutics announces FDA approval of AUVELITY for Alzheimer's agitation, marking first-in-class treatment for critical unmet medical need.
AC Immune Advances ACI-24 Alzheimer's Trial to Final Cohort, Initiates ACI-19764 Phase 1 Study
AC Immune progresses ACI-24 Alzheimer's treatment to final trial phase while starting new brain-penetrant NLRP3 inhibitor study in Q1 2026 update.